06:42:12 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-11-08 Kvartalsrapport 2024-Q3
2024-08-16 Kvartalsrapport 2024-Q2
2024-05-23 Bonusutdelning RAY B 1.3
2024-05-23 Ordinarie utdelning RAY B 0.70 SEK
2024-05-22 Årsstämma 2024
2024-05-17 Kvartalsrapport 2024-Q1
2024-02-23 Bokslutskommuniké 2023
2023-11-17 Kvartalsrapport 2023-Q3
2023-08-25 Kvartalsrapport 2023-Q2
2023-05-26 Ordinarie utdelning RAY B 0.00 SEK
2023-05-25 Årsstämma 2023
2023-05-17 Kvartalsrapport 2023-Q1
2023-02-28 Bokslutskommuniké 2022
2022-11-29 Kvartalsrapport 2022-Q3
2022-08-29 Kvartalsrapport 2022-Q2
2022-05-27 Ordinarie utdelning RAY B 0.00 SEK
2022-05-25 Årsstämma 2022
2022-05-18 Kvartalsrapport 2022-Q1
2022-02-23 Bokslutskommuniké 2021
2021-11-18 Kvartalsrapport 2021-Q3
2021-08-25 Kvartalsrapport 2021-Q2
2021-05-27 Ordinarie utdelning RAY B 0.00 SEK
2021-05-26 Årsstämma 2021
2021-05-05 Kvartalsrapport 2021-Q1
2021-02-23 Bokslutskommuniké 2020
2020-11-18 Kvartalsrapport 2020-Q3
2020-08-26 Kvartalsrapport 2020-Q2
2020-07-01 Ordinarie utdelning RAY B 0.00 SEK
2020-06-30 Årsstämma 2020
2020-05-05 Kvartalsrapport 2020-Q1
2020-02-14 Bokslutskommuniké 2019
2019-11-14 Kvartalsrapport 2019-Q3
2019-08-20 Kvartalsrapport 2019-Q2
2019-05-22 Ordinarie utdelning RAY B 0.00 SEK
2019-05-21 Årsstämma 2019
2019-05-09 Kvartalsrapport 2019-Q1
2019-02-20 Bokslutskommuniké 2018
2018-11-15 Kvartalsrapport 2018-Q3
2018-08-23 Kvartalsrapport 2018-Q2
2018-05-31 Ordinarie utdelning RAY B 0.00 SEK
2018-05-29 Årsstämma 2018
2018-05-09 Kvartalsrapport 2018-Q1
2018-02-15 Bokslutskommuniké 2017
2017-11-22 Kvartalsrapport 2017-Q3
2017-08-24 Kvartalsrapport 2017-Q2
2017-05-24 Ordinarie utdelning RAY B 0.00 SEK
2017-05-23 Årsstämma 2017
2017-05-19 Kvartalsrapport 2017-Q1
2017-02-17 Bokslutskommuniké 2016
2016-11-18 Kvartalsrapport 2016-Q3
2016-08-25 Kvartalsrapport 2016-Q2
2016-05-18 Ordinarie utdelning RAY B 0.25 SEK
2016-05-17 Årsstämma 2016
2016-05-12 Kvartalsrapport 2016-Q1
2016-02-18 Bokslutskommuniké 2015
2015-11-25 Kvartalsrapport 2015-Q3
2015-08-28 Kvartalsrapport 2015-Q2
2015-05-29 Ordinarie utdelning RAY B 0.00 SEK
2015-05-28 Årsstämma 2015
2015-05-08 Kvartalsrapport 2015-Q1
2015-02-12 Bokslutskommuniké 2014
2014-11-27 Kvartalsrapport 2014-Q3
2014-08-27 Kvartalsrapport 2014-Q2
2014-05-28 Ordinarie utdelning RAY B 0.00 SEK
2014-05-27 Årsstämma 2014
2014-05-16 Kvartalsrapport 2014-Q1
2014-02-13 Bokslutskommuniké 2013
2013-11-27 Kvartalsrapport 2013-Q3
2013-08-28 Kvartalsrapport 2013-Q2
2013-05-23 Ordinarie utdelning RAY B 0.00 SEK
2013-05-22 Årsstämma 2013
2013-05-16 Kvartalsrapport 2013-Q1
2013-02-14 Bokslutskommuniké 2012
2012-11-16 Kvartalsrapport 2012-Q3
2012-08-28 Kvartalsrapport 2012-Q2
2012-05-31 Ordinarie utdelning RAY B 0.00 SEK
2012-05-30 Årsstämma 2012
2012-05-23 Kvartalsrapport 2012-Q1
2012-02-16 Bokslutskommuniké 2011
2011-11-24 Kvartalsrapport 2011-Q3
2011-05-26 Ordinarie utdelning RAY B 0.50 SEK
2011-05-25 Årsstämma 2011
2011-05-04 Kvartalsrapport 2011-Q1
2011-02-18 Bokslutskommuniké 2010
2010-11-12 Kvartalsrapport 2010-Q3
2010-08-27 Kvartalsrapport 2010-Q2
2010-05-26 Ordinarie utdelning RAY B 0.50 SEK
2010-05-25 Årsstämma 2010
2010-05-11 Kvartalsrapport 2010-Q1
2009-11-20 Kvartalsrapport 2009-Q3
2009-08-27 Kvartalsrapport 2009-Q2
2009-05-27 Ordinarie utdelning RAY B 0.00 SEK
2009-05-26 Årsstämma 1
2009-05-15 Kvartalsrapport 2009-Q1
2008-06-25 Split RAY B 1:3
2003-06-10 Split RAY B 20:1

Beskrivning

LandSverige
ListaMid Cap Stockholm
SektorHälsovård
IndustriMedicinteknik
RaySearch Laboratories är verksamt inom medicinteknik. Bolaget är specialiserat inom utveckling av mjukvarulösningar för sjukvårdsindustrin. Bolagets produkter används främst inom behandling av cancer och andra allvarliga sjukdomar, och vidaresäljs som dosplanerings- respektive informationssystem. Olika funktioner inkluderar maskininlärning, beräkningshastighet, automatiserad planering, virtuell simulering, adaptiv terapi och digitala arbetsflöden. Produkterna används av ett flertal kliniker.
2023-10-02 22:02:35

RaySearch Laboratories AB (publ) is proud to announce the continued commitment with Mevion Medical Systems, the leading global provider of compact proton therapy solutions, to develop new proton therapy solutions in support of current and emerging technologies. Together RaySearch and Mevion re-imagine novel solutions to advance the use of new proton therapy technologies and empower medical providers to rapidly and efficiently bring next-generation proton therapy services to their patients. 

The collaboration leverages both companies' domain expertise in the advancement of innovative solutions for HYPERSCAN IMPT, adaptive therapy, proton arc therapy, and FLASH proton therapy. Key development areas are:
  • RayStation®* treatment planning system: RaySearch is optimizing treatment planning algorithms to advance the use of the HYPERSCAN PBS technology. One of the upcoming goals is to further develop existing algorithms to support upright treatments of the new ultra-compact MEVION S250-FIT proton therapy platform.
  • RayCare®* oncology information system: RayCare is designed to efficiently support complex and advanced clinical processes such as adaptive therapy. Mevion has integrated in-room diagnostic CT imaging on the MEVION S250i and MEVION S250-FIT platforms to optimize the use of adaptive therapy. RaySearch and Mevion will join forces to streamline and standardize the delivery of adaptive proton therapy treatments by integrating these technologies. 
  • Proton arc therapy: Arc therapy is an emerging proton therapy treatment delivery technique that optimizes rotational techniques of a gantry or upright patient positioner to conform and precisely target a tumor from multiple angles. Mevion technology has unique capabilities with the HYPERSCAN PBS technology with pMLC, fast energy switching, and integrated robotic motion control capabilities. RaySearch is developing treatment planning algorithms in RayStation to use these advanced technologies. 
  • FLASH proton therapy: FLASH proton therapy is an investigational solution that delivers a high dose in a short period of time with the goal of substantially reducing treatment times and minimizing damage to healthy tissue and critical organs. RaySearch and Mevion are combining their strengths to enhance the accessibility and efficiency of FLASH, while facilitating its transition from research to clinical application.

Tina Yu, Ph.D., CEO and President of Mevion Medical Systems, says: "The synergy between Mevion Medical Systems and RaySearch Laboratories continues to redefine the landscape of cancer care. The united strength of our collaborative partnership is accelerating the deployment of emerging proton therapy developments. We are committed to breaking down technological and clinical access barriers to superior proton therapy technology."

Johan Löf, founder and CEO, RaySearch, says: "RaySearch's expertise in oncology software and Mevion Medical Systems' latest technological advancements will continue to bring innovation in the proton therapy field and we look forward to working together with Mevion to further advance proton cancer treatments."